Kheiron raises £17.8m Series A led by Atomico to expand clinical validation of its breast cancer AI software
Atomico led the Series A round with participation from Connect Ventures, Greycroft, Hoxton Ventures, and EXOR Seeds.
Kheiron Medical Technologies is an applied science company that builds machine learning software to support cancer diagnostics and improve patient outcomes.
Kheiron Medical Technologies has secured £17.8m in a Series A funding round led by Atomico. The investment also drew participation from Connect Ventures, Greycroft, Hoxton Ventures, and EXOR Seeds. The capital will be deployed to expand clinical validation for the company's breast cancer detection software, Mia, through large-scale clinical trials and international roll-outs across Europe, the United States, and Asia.
The London-based firm aims to address mounting pressures on radiology departments by helping clinicians analyse mammography images more accurately. Atomico Principal Irina Haivas will join the board as part of the transaction.
From the founder
"The foundation of Kheiron’s approach to rigorous development and testing is to ensure reliably improved patient outcomes and safety by helping doctors in their daily practice,"
Peter Kecskemethy
CEO at Kheiron Medical Technologies
Investor perspective
"Cancer care today is defined by fear and uncertainty but we believe we are on the cusp of a new age when AI-supported approaches to diagnostics will enable earlier and more accurate detection, tracking, and as a result better treatment outcomes,"
Irina Haivas
Partner, Atomico
Use of funds
- 01Expand into international markets
Investors
.png)
Categories
About the company
Kheiron Medical Technologies
Kheiron develops machine learning software to assist radiologists with breast cancer detection.